A patient with type 2 diabetes is prescribed miglitol, an alpha-glucosidase inhibitor. How does miglitol differ pharmacokinetically from acarbose?
- A Miglitol is systemically absorbed whereas acarbose acts locally in the gut lumen
- B Miglitol inhibits alpha-amylase whereas acarbose does not
- C Both A and C ✓
- D Miglitol requires dose adjustment in renal impairment whereas acarbose does not
Correct answer: C. Both A and C
Explanation
Miglitol is systemically absorbed and requires dose adjustment in renal impairment, while acarbose acts locally in the gut lumen and does not require renal dose adjustment. Miglitol also inhibits alpha-amylase in addition to alpha-glucosidase (B is incomplete alone). The combination of A and D makes C the most complete and correct answer.
Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.